Navigation Links
UNC study supports role of circadian clock in response to chemotherapy
Date:1/13/2009

CHAPEL HILL For years, research has hinted that the time of day that cancer patients receive chemotherapy can impact their chances of survival. But the lack of a clear scientific explanation for this finding has kept clinicians from considering timing as a factor in treatment.

Now, a new study from the University of North Carolina at Chapel Hill has suggested that treatment is most effective at certain times of day because that is when a particular enzyme system one that can reverse the actions of chemotherapeutic drugs is at its lowest levels in the body.

The study, performed in mice, could also have implications for the prevention of new cancers.

The enzyme system implicated called nucleotide excision repair repairs many types of DNA damage that come not just from chemotherapy but also from the ultraviolet rays of the sun. Thus, by understanding the cyclical nature of this system, physicians may be able to pinpoint when it is most crucial for people to protect themselves from sun exposure to minimize their risk of skin cancer.

"Timing is everything, and here we have molecular data showing why this is especially true with regard to cancer," said senior study author Aziz Sancar, M.D., Ph.D., a member of the UNC Lineberger Comprehensive Cancer Center and Sarah Graham Kenan professor of biochemistry and biophysics in the UNC School of Medicine. Sancar is also a member of the National Academy of Sciences and the Turkish Academy of Sciences. "By hitting cancer cells with chemo at a time when their ability to repair themselves is minimal, you should be able to maximize effectiveness and minimize side effects of treatment."

The study, set to appear this week in the online early edition of the Proceedings of the National Academy of Sciences, provides the first solid evidence that the daily oscillations of the cell's repair machinery can affect the potency of cancer drugs.

The primary driver of this os
'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Medical study shows epidurals and spinal anesthetics are safer than previously reported
2. InterMune Reports Results from Triple Combination Study of ITMN-191
3. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
4. Lupus is a Significant Cost to Employers, According to Thomson Reuters Study
5. Penn study: Chances of surviving cardiac arrest depend on where patients are treated
6. Study: Fluoridation Benefits Doubtful
7. U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention
8. Study Finds More Effective Treatment for Pneumonia Following Influenza
9. Study finds more effective treatment for pneumonia following influenza
10. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
11. Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Wolters ... healthcare professionals and students, announced today that in a ... confirmed that use of the clinical decision support resource ... the end of 2014, UpToDate users in more than ... topics per month, on average. In Germany alone, 95% ...
(Date:5/6/2015)... TX (PRWEB) May 06, 2015 ... 1,000 user mark after launching in mid-February. The company ... candidates who have previous experience in the industry. Likewise, ... profession. , According to Kyle Johnson, CTO, unique traffic ... to the first month: "Each new job posting brings ...
(Date:5/6/2015)... 06, 2015 Locally owned, Greek olive oil ... this past week as having one the best Extra Virgin ... from the Peloponnese region of Greece and known as ... the category of Medium Olive Oil, which is defined by ... With over 700 producer applicants from 25 different countries ...
(Date:5/6/2015)... Dr. Vito C. Quatela, one of upstate New York’s ... medical mission trip to Hanoi, Vietnam with the HUGS Foundation ... and other deformities of the face. , During the 10-day ... 26, Dr. Quatela and his team performed microtia surgeries on ... the outside of the ear is underdeveloped. This condition is ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4
... completely implantable artificial heart was approved by the U.S. ... heart has been approved for patients with severe heart ... ,Under the FDA's Humanitarian Use Device provisions, ... However, it restricts the use of more than 4,000 ...
... 300 million poultry next month against bird flu.// ... large-scale criticism over the country's efforts to stamp out ... mass vaccination today. Indonesia has the world's highest human ... in the world and scientists and the World Bank ...
... An engineer has developed a new system that could help ... ,An engineer Fernando Silvio Nu?o Almirantearena has developed a ... heart attack, brain stroke or high blood pressure, by determining ... techniques. Fernando has outlined in his thesis for PhD the ...
... in the Journal of Clinical Investigation and the September issue ... that a new drug helps in reducing the risk of ... flow in diseased arteries. The new drug developed by ... by free radicals, which helps in dilatation of the arteries. ...
... worked at Ground Zero after 9/11 are struggling with serious ... advocates.// "When we were needed on 9/11, no one asked ... said Lucelly Gil, who was present in the disaster zone. ... illegal immigrants to work in danger zone without providing the ...
... asked EU health authorities to re-examine data related to ... Committee for Medicinal Products for Human Use (CHMP) had ... cancer need new treatment options like Tarceva, which has ... and has already been approved for this indication in ...
Cached Medicine News:Health News:First Implantable artificial heart gets FDA’s approva 2Health News:Indonesia To Conduct Mass Vaccination Of Poultry 2Health News:A New System Developed For Studying The Condition Of The Human Arterial System 2Health News:A New Drug That Could Revolutionize Management Of Heart Disease 2
(Date:5/6/2015)... , May 06, 2015 Research and Markets ... addition of the "Asia-Pacific Internal Trauma Fixation ... Analysis and Forecast To 2019" report to ... Fixation Devices market is estimated to grow at ... Factors, such as technological advancement, rising incidences of ...
(Date:5/6/2015)... DIEGO , May 6, 2015  MEI Pharma, Inc. ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at the Bank of America Merrill Lynch ... 8:00 a.m. Pacific time from the Encore at the Wynn ... of the presentation can be accessed at www.meipharma.com . ...
(Date:5/6/2015)... 6, 2015 Adaptive Biotechnologies, a leader ... T-cell and B-cell receptors in the immune system, ... financing round with a $195 million investment to ... led by Matrix Capital Management and included other ... Springs Capital and an additional large healthcare investor, ...
Breaking Medicine Technology:Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2MEI Pharma to Present at Bank of America Merrill Lynch Health Care Conference 2Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment 2
... MYL ) today announced its financial results for the ... , Adjusted diluted EPS of $0.52 for the three ... prior year period, an increase of 18%; , Adjusted ... 31, 2012 compared to $1.45 billion for the same prior year ...
...  Galenea Corp., a leader in the rapidly emerging ... Stanley Medical Research Institute (SMRI) will provide $6 ... development of Galenea,s innovative pro-cognitive discovery program and ... treatment of schizophrenia and other psychiatric disorders.  The ...
Cached Medicine Technology:Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 2Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 4Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 5Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 6Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 7Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 8Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 9Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 10Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 11Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 12Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 13Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 2Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 3
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of ... run up to 12 Criterion gels in a ... (13.3 x 8.7 cm) than the traditional mini ... strips to give you the optimal combination of ...
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The ElectroXpress gel electrophoresis system mirrors a ... high-throughput screening of PCR products to take ... the source (96-well) plate. Loading can be carried ... the first time in the industry two ...
Medicine Products: